What is the appropriate treatment for a urine culture that grows yeast?

Treatment of Yeast-Positive Urine Culture

Most patients with yeast in their urine do NOT require antifungal treatment—remove the urinary catheter if present and observe, as candiduria often resolves spontaneously in asymptomatic patients. 1

When to Treat vs. When to Observe

The critical first decision is determining whether antifungal therapy is actually needed. According to the 2016 IDSA guidelines, treatment with antifungal agents is NOT recommended unless the patient belongs to a high-risk group 1. This is a strong recommendation based on the understanding that most candiduria represents colonization rather than true infection.

High-Risk Patients Who REQUIRE Treatment:

• Neutropenic patients (treat as candidemia)
• Very low-birth-weight infants <1500g (treat as candidemia)
• Patients undergoing urologic procedures (prophylactic treatment)
• Symptomatic patients with cystitis or pyelonephritis
• Patients with urinary tract obstruction or structural abnormalities

Low-Risk Patients Who Do NOT Require Treatment:

• Asymptomatic patients with indwelling catheters
• Patients without neutropenia or immunosuppression
• Patients not undergoing urologic manipulation

Essential Non-Pharmacologic Management

Before or concurrent with any antifungal therapy, removal of the indwelling bladder catheter is strongly recommended if feasible 1. This single intervention resolves candiduria in approximately 50% of cases 2. Additionally:

• Eliminate urinary tract obstruction (strong recommendation) 1
• Remove or replace nephrostomy tubes/stents if present 1
• Optimize glycemic control in diabetic patients 3
• Discontinue unnecessary broad-spectrum antibiotics 4

Antifungal Treatment Regimens

For Candida Cystitis (Lower Tract Infection)

First-line for fluconazole-susceptible organisms:

• Oral fluconazole 200 mg (3 mg/kg) daily for 2 weeks 1 (strong recommendation)

This is the preferred agent because fluconazole achieves high urinary concentrations, is available orally, and has proven efficacy 1, 4, 5.

For fluconazole-resistant C. glabrata:

• Amphotericin B deoxycholate 0.3–0.6 mg/kg daily for 1–7 days 1 (strong recommendation)
• OR oral flucytosine 25 mg/kg four times daily for 7–10 days 1 (strong recommendation)

For C. krusei:

• Amphotericin B deoxycholate 0.3–0.6 mg/kg daily for 1–7 days 1 (strong recommendation)

Alternative for resistant species:

• Amphotericin B bladder irrigation (50 mg/L sterile water daily for 5 days) may be useful for fluconazole-resistant species 1 (weak recommendation)

For Candida Pyelonephritis (Upper Tract Infection)

First-line for fluconazole-susceptible organisms:

• Oral fluconazole 200–400 mg (3–6 mg/kg) daily for 2 weeks 1 (strong recommendation)

For fluconazole-resistant C. glabrata:

• Amphotericin B deoxycholate 0.3–0.6 mg/kg daily for 1–7 days with or without oral flucytosine 25 mg/kg four times daily 1 (strong recommendation)
• Monotherapy with flucytosine 25 mg/kg four times daily for 2 weeks could be considered 1 (weak recommendation)

For C. krusei:

• Amphotericin B deoxycholate 0.3–0.6 mg/kg daily for 1–7 days 1 (strong recommendation)

For Patients Undergoing Urologic Procedures (Prophylaxis)

Treat several days before and after the procedure with:

• Oral fluconazole 400 mg (6 mg/kg) daily 1 (strong recommendation)
• OR Amphotericin B deoxycholate 0.3–0.6 mg/kg daily 1 (strong recommendation)

Critical Pitfalls and Caveats

Echinocandins Are NOT Recommended

Despite their excellent activity against Candida in bloodstream infections, echinocandins do not achieve adequate urinary concentrations and should not be used for urinary tract candidiasis 5, 2. While small case series show occasional success, failures have occurred, making them unreliable for this indication.

Newer Azoles Are Also Inadequate

Voriconazole, posaconazole, and isavuconazole similarly fail to achieve sufficient urine levels and are not recommended for isolated urinary tract infections 2.

Species Identification Is Essential

Obtain species identification and susceptibility testing when treatment is being considered 6. This is crucial because:

• C. albicans is typically fluconazole-susceptible
• C. glabrata is often fluconazole-resistant (dose-dependent susceptibility)
• C. krusei is intrinsically fluconazole-resistant
• Treatment failure is common when empiric fluconazole is used for resistant species

Distinguish Colonization from Infection

Pyuria and colony counts cannot differentiate colonization from true infection, especially with indwelling catheters 1. Base treatment decisions on:

• Patient symptoms (dysuria, frequency, urgency, flank pain, fever)
• Risk factors for dissemination
• Planned urologic procedures
• Imaging findings (hydronephrosis, abscesses, fungus balls)

Fungus Balls Require Additional Intervention

If imaging reveals fungus balls (aggregations of mycelia and yeasts causing obstruction), systemic antifungals alone are insufficient 1, 5. These patients require:

• Surgical intervention (strong recommendation) 1
• Irrigation through nephrostomy tubes with amphotericin B 25–50 mg in 200–500 mL sterile water 1 (strong recommendation)
• Systemic antifungal therapy as outlined above

Neonates and Very Low-Birth-Weight Infants

These patients should be treated as candidemia with more aggressive regimens, including imaging of the genitourinary tract, lumbar puncture, and dilated retinal examination 1.

Monitoring and Follow-Up

• Routine post-treatment urine cultures are not indicated for asymptomatic patients who respond to therapy
• For persistent symptoms or early recurrence, repeat urine culture with susceptibility testing
• Consider imaging (ultrasound or CT) if symptoms persist despite appropriate therapy to evaluate for complications like abscesses or obstruction 1